Last update:

   06-Sep-2012
 

Arch Hellen Med, 29(3), May-June 2012, 279-289

REVIEW

Current trends in the diagnosis and treatment of cholangiocarcinoma

L. Vasilieva,1 S.I. Papadhimitriou,2 S.P. Dourakis1
1Second Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, "Hippokration" Regional General Hospital, Athens,
2Unit of Molecular Cytogenetics, Laboratory of Hematology, "G. Genimatas" Regional General Hospital, Athens, Greece

Cholangiocarcinoma (CCA) is a very aggressive tumor with poor survival, the diagnosis of which is increasing. Although its cause is still unknown in most cases it is attributed to inflammatory conditions, including primary sclerosing cholangiitis, liver fluke infestation, and hepatolithiasis, but progress in molecular pathogenesis has revealed the importance of genetic alterations. The diagnosis of CCA is difficult, mainly because access to the tumor is not easy. Biopsy is possible only for intrahepatic CCA, which accounts for 10% of cases. Routine brush cytology from endoscopic retrograde cholangiography has high specificity (100%) but unfortunately it is of low sensitivity (in the range of 30%). The treatment of CCA is challenging as it is usually difficult to determine when radical surgical treatment, local resection or liver transplantation is possible, and its prognosis is still dismal. This is a review of the evolution of diagnostic techniques for CCA from routine brush cytology to modern molecular techniques, and in particular fluorescence in situ hybridization (FISH) and digital image analysis (DIA), and of its treatment.

Key words: Cholangiocarcinoma, Digital image analysis (DIA), Fluorescence in situ hybridization (FISH), Treatment.


© Archives of Hellenic Medicine